KALAMAZOO – Armune BioScience has appointed David Esposito as Chief Operating Officer. In the newly created role, Esposito will be responsible for commercial strategy for Apifiny, an innovative prostate cancer diagnostic assay, and expansion of the company?s sales and marketing efforts.
Armune BioScience is a medical diagnostics company formed to develop and commercialize unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. The company has corporate headquarters in Kalamazoo and a research and commercial laboratory in Ann Arbor.
“David brings the right expertise as Armune BioScience prepares to commercialize the first of what will be a number of promising diagnostic and prognostic technologies,? said Eli Thomssen, President and CEO of Armune BioScience. ?His wealth of experience in the diagnostic and pharmaceutical markets will help Armune BioScience reach its full potential.?
Esposito?s rich and diverse experience includes serving as President and General Manager of Phadia U.S. Inc., a leading specialty diagnostics company. Before his time with Phadia, he served at Merck & Co. for 15 years in several key roles in sales, marketing and commercial strategy.
“I?m thrilled to join the team at Armune BioScience at such an exciting time as we prepare to commercialize Apifiny, the first of many breakthrough diagnostic tests,? Esposito said. ?The proprietary technologies of Armune BioScience have significant potential to meet areas of crucial need in prostate, lung and breast cancer diagnostic and prognostic testing. I look forward to helping the team prepare and execute on the commercial opportunities.?
